Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression

Fatemat Hassan, Sarath Meduru, Kazuaki Taguchi, M. Lakshmi Kuppusamy, Mahmoud Mostafa, Periannan Kuppusamy, Mahmood Khan

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Adult stem cells have shown great promise toward repairing infarcted heart and restoring cardiac function. Mesenchymal stem cells (MSCs), because of their inherent multipotent nature and their ability to secrete a multitude of growth factors and cytokines, have been used for cardiac repair with encouraging results. Preclinical studies showed that MSCs injected into infarcted hearts improve cardiac function and attenuate fibrosis. Although stem cell transplantation is a promising therapeutic option to repair the infarcted heart, it is faced with a number of challenges, including the survival of the transplanted cells in the ischemic region, due to excessive oxidative stress present in the ischemic region. The objective of this study was to determine the effect of Carvedilol (Carv), a nonselective β-blocker with antioxidant properties, on the survival and engraftment of MSCs in the infarcted heart. MSCs were subjected to a simulated host-tissue environment, similar to the one present in the infarcted myocardium, by culturing them in the presence of hydrogen peroxide (H2O2) to induce oxidative stress. MSCs were treated with 2.5 μM Carv for 1 h in serum-free medium, followed by treatment with H2O2 for 2 h. The treated cells exhibited significant protection against H2O2-induced cell death versus untreated controls as determined by 3-(4,5-dimethylthiazolyl-2)-2,5- diphenyltetrazolium bromide and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assays. Likewise, transplantation of MSCs after permanent left coronary artery ligation and treatment of animals after myocardial infarction (MI) with Carv (5 mg/kg b.wt.) led to significant improvement in cardiac function, decreased fibrosis, and caspase-3 expression compared with the MI or MSC-alone groups.

Original languageEnglish
Pages (from-to)62-71
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Issue number1
Publication statusPublished - 2012 Oct
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression'. Together they form a unique fingerprint.

Cite this